Search - tctmd.com

Displaying 801 - 820 of 1111

Sort: Relevancy | Date

News Industry News

New Study Demonstrates Potential Benefits of Shorter-Term Dual Antiplatelet Therapy in Patients Treated With a Second Generation Drug-Eluting Stent

October 31, 2013

News Industry News

Genetic Profiling May Provide Clinical Benefit by Identifying Heart Attack Patients That Are Resistant to Blood Thinners

October 31, 2013

Presentation TCT 2013

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

Presenter: Matthew Price

October 30, 2013

News Conference News TCT 2013

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

October 30, 2013

News Conference News TCT 2013

Innovation in Intervention: Perspectives from Industry

October 30, 2013

Presentation TCT 2013

Twelve-Month Clinical Outcomes from the Optimal Duration of Dual Antiplatelet Therapy Following Treatment with Endeavor (Zotarolimus-Eluting Stent) in Real-World Japanese Patients with Coronary Artery

Presenter: Masato Nakamura

October 29, 2013

Presentation TCT 2013

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

Presenter: Byoung Kwon Lee

October 29, 2013

Presentation TCT 2013

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

Presenter: Laura Mauri

October 29, 2013

News Industry News

OrbusNeich’s COMBO™ Dual Therapy Stent Shows Excellent Early Healing and Durable Outcomes out to 24 Months

October 29, 2013

News Conference News TCT 2013

Data Evolving for Pharmacological Treatment Strategies for Patients with AF and Valvular Heart Disease

October 29, 2013

News Conference News TCT 2013

Cre8, BioFreedom Polymer-Free DES Show Promise

October 28, 2013

News Conference News TCT 2013

COMFORTABLE AMI: Biolimus-Eluting Stent Bests BMS in STEMI

October 28, 2013

Presentation TCT 2013

LAA Closure in Patients Who Need Dual Antiplatelet Therapy: Rationale and Results

Presenter: Zoltan Turi

October 27, 2013

News Daily News

Innovative Stent-Grafts Safe, Feasible for High-Risk Complex Aortic Aneurysms

Yael L. Maxwell

October 25, 2013

News Daily News

Longer DAPT Duration Reduces Adverse Events After PCI for In-Stent Restenosis

Caitlin E. Cox

October 23, 2013

News Industry News

Medtronic to Unveil CoreValve U.S. Pivotal Trial Results at TCT 2013

October 17, 2013

News Daily News

EXECUTIVE: Xience Performs Well in Patients with Less Complex Multivessel Disease

October 15, 2013

News Daily News

Study Challenges Guidelines Regarding Delay for Noncardiac Surgery After PCI

L.A. McKeown

October 11, 2013

News Daily News

Long-term Aspirin as Effective as Dual Therapy in Uncomplicated DES Patients

Jason Kahn

October 11, 2013

News Daily News

La Aspirina a Largo Plazo es tan Eficaz como la Terapia Doble en Pacientes SLF Sin Complicaciones

Jason Kahn

October 11, 2013

Advertisement

New Study Demonstrates Potential Benefits of Shorter-Term Dual Antiplatelet Therapy in Patients Treated With a Second Generation Drug-Eluting Stent

Genetic Profiling May Provide Clinical Benefit by Identifying Heart Attack Patients That Are Resistant to Blood Thinners

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

Innovation in Intervention: Perspectives from Industry

Twelve-Month Clinical Outcomes from the Optimal Duration of Dual Antiplatelet Therapy Following Treatment with Endeavor (Zotarolimus-Eluting Stent) in Real-World Japanese Patients with Coronary Artery

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

OrbusNeich’s COMBO™ Dual Therapy Stent Shows Excellent Early Healing and Durable Outcomes out to 24 Months

Data Evolving for Pharmacological Treatment Strategies for Patients with AF and Valvular Heart Disease

Cre8, BioFreedom Polymer-Free DES Show Promise

COMFORTABLE AMI: Biolimus-Eluting Stent Bests BMS in STEMI

LAA Closure in Patients Who Need Dual Antiplatelet Therapy: Rationale and Results

Innovative Stent-Grafts Safe, Feasible for High-Risk Complex Aortic Aneurysms

Longer DAPT Duration Reduces Adverse Events After PCI for In-Stent Restenosis

Medtronic to Unveil CoreValve U.S. Pivotal Trial Results at TCT 2013

EXECUTIVE: Xience Performs Well in Patients with Less Complex Multivessel Disease

Study Challenges Guidelines Regarding Delay for Noncardiac Surgery After PCI

Long-term Aspirin as Effective as Dual Therapy in Uncomplicated DES Patients

La Aspirina a Largo Plazo es tan Eficaz como la Terapia Doble en Pacientes SLF Sin Complicaciones

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content